Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy

Cancer Immunology, Immunotherapy

Volumn 65, Issue 4, 2016, Pages 371-382

  Medrano, Ruan Felipe Vieira ^a   Catani, João Paulo Portela ^a   Ribeiro, Aline Hunger ^a   Tomaz, Samanta Lopes ^b   Merkel, Christian A ^a   Costanzi Strauss, Eugenia ^a   Strauss, Bryan E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adenovirus; Cell death; Immunotherapy; Interferon beta; Melanoma; p19Arf

Indexed keywords

APO1 PROTEIN; BETA INTERFERON; CANCER VACCINE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH RECEPTOR 5; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 6; KILLER DEATH RECEPTOR 5; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; ULBP1 PROTEIN; UNCLASSIFIED DRUG; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL INFILTRATION; CELL MIGRATION; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; EOSINOPHIL; FEMALE; GENE TRANSFER; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; MELANOMA CELL; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION; ANIMAL; C57BL MOUSE; GENE THERAPY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; METABOLISM; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PROCEDURES; SCID MOUSE; TH1 CELL; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENETIC THERAPY; IMMUNOTHERAPY; INTERFERON-BETA; INTERLEUKIN-15; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TH1 CELLS; TUMOR BURDEN; VACCINATION;

EID: 84958741104     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1807-8     Document Type: Article

References (25)

1. Lu M, Miller P, Lu X (2014) Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy. FEBS Lett 588:2616–2621
2. Sherr CJ (2006) Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6:663–673
3. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D (1999) Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1:20–26
4. Kaufman HL, Kirkwood JM, Hodi FS et al (2013) The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 10:588–598
5. Thalanayar PM, Agarwala SS, Tarhini AA (2014) Melanoma adjuvant therapy. Chin Clin Oncol 3:26
6. Diamond MS, Kinder M, Matsushita H et al (2011) Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208:1989–2003
7. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, Williams BR (2001) Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69:912–920
8. Bajgelman MC, Strauss BE (2008) Development of an adenoviral vector with robust expression driven by p53. Virology 371:8–13
9. Merkel CA, Medrano RF, Barauna VG, Strauss BE (2013) Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanoma in vitro and in vivo. Cancer Gene Ther 20:317–325
10. Oba-Shinjo SM, Correa M, Ricca TI et al (2006) Melanocyte transformation associated with substrate adhesion impediment. Neoplasia 8:231–241
11. Keil D, Luebke RW, Pruett SB (2001) Quantifying the relationship between multiple immunological parameters and host resistance: probing the limits of reductionism. J Immunol 167:4543–4552
12. Budzynski W, Radzikowski C (1994) Cytotoxic cells in immunodeficient athymic mice. Immunopharmacol Immunotoxicol 16:319–346
13. Shultz LD, Schweitzer PA, Christianson SW et al (1995) Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 154:180–191
14. Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72
15. Kepp O, Galluzzi L, Martins I et al (2011) Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 30:61–69
16. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G (2002) Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195:327–333
17. Mocikat R, Braumuller H, Gumy A et al (2003) Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 19:561–569
18. Wong JL, Berk E, Edwards RP, Kalinski P (2013) IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res 73:4653–4662
19. Iannello A, Thompson TW, Ardolino M, Lowe SW, Raulet DH (2013) p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 210:2057–2069
20. Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A (2011) Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res 71:5998–6009
21. Rodrigues L, Bonorino C (2009) Role of IL-15 and IL-21 in viral immunity: applications for vaccines and therapies. Expert Rev Vaccines 8:167–177
22. Croce M, Orengo AM, Azzarone B, Ferrini S (2012) Immunotherapeutic applications of IL-15. Immunotherapy 4:957–969
23. Sutherland CL, Rabinovich B, Chalupny NJ, Brawand P, Miller R, Cosman D (2006) ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood 108:1313–1319
24. Yoon SR, Kim TD, Choi I (2015) Understanding of molecular mechanisms in natural killer cell therapy. Exp Mol Med 47:e141
25. Wang Y, Swiecki M, Cella M, Alber G, Schreiber RD, Gilfillan S, Colonna M (2012) Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe 11:631–642